Sixty degrees pharmaceuticals to ensure continuity of tafenoquine supply in u.s. by importing limited quantity of kodatef®

Washington, feb. 11, 2025 (globe newswire) -- 60 degrees pharmaceuticals, inc. (nasdaq: sxtp; sxtpw) (“60 degrees” or the “company”), pharmaceutical company today announced that the united states food and drug administration (fda) does not object to the company's plan to import kodatef® (tafenoquine) from australia as a one-time, preemptive measure against any near-term disruption in the u.s. supply of arakoda® (tafenoquine). arakoda is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older in the united states (u.s.) it is sold under the brand name kodatef in australia, where it is indicated for the prevention of malaria in adults 18 years of age and above.
SXTP Ratings Summary
SXTP Quant Ranking